GSK’s Walmsley On US v. EU COVID-Flu Combos, RSV Branding, And Investing In Infectious Disease

 
• By Sarah Karlin-Smith

COVID vaccine makers already licensed in the US will have a leg up on in the combination respiratory vaccine space since aspiring new entrants like GSK will have to do efficacy work to get FDA approval. CEO Walmsley offers insight into the company’s vaccine strategy.

Vaccine vials with GSK logo in background
GSK executives touted the company’s vaccine plans at the site of its new acquisition Affinivax along BIO 2023. • Source: Shutterstock/Golden Shrimp

More from Vaccines

More from Pink Sheet